Sympatient

Founded in 2017 in Hamburg, Germany, Sympatient GmbH develops digital therapeutics aimed at treating anxiety disorders. also participating.075 mn.Sympatient offers innovative digital therapeutics (DTx), primarily centered around their flagship product, the Invirto® therapy. This is recognized as the first digital anxiety therapy that employs a combination of virtual reality exposure treatment with app-based cognitive behavioral therapy (CBT) for patients grappling with conditions such as agoraphobia, social phobia, or panic disorder. The Invirto® therapy empowers patients to engage in therapy from the comfort of their homes, thereby enhancing accessibility and convenience. The platform is designed to work in tandem with healthcare professionals, allowing therapists to utilize the DTx to optimize treatment outcomes, while also enabling patients to adopt self-directed therapy post-diagnosis.Sympatient generates revenue through a model that integrates partnerships with healthcare providers and insurance companies, allowing for reimbursement of their digital therapy offerings. The Invirto® therapy, as a recognized DiGA (Digital Health Application), is fully covered for 72 million insured individuals in Germany, which facilitates seamless access for patients and encourages broader adoption among therapists and clinics. Transactions typically occur through direct partnerships with healthcare entities, where Sympatient provides its digital solutions as part of a comprehensive patient care strategy. This includes a blended care approach that combines digital therapy with traditional in-person therapeutic sessions, thereby enhancing the overall treatment experience. Specific geographic regions targeted for expansion have yet to be disclosed.

1. Series A

   Jun 23, 2022

   Amount

   $7.9M

   Investors

   Locked

2. Seed

   May 28, 2020

   Amount

   $1.8M

   Investors

   Locked